A multicenter,openlabel,randomized controlled traial for the head-to-head comparison of minodronic acid hydroate and raloxifene hydrocloride

Conditions

Osteoporosis

Ohta H, Uemura Y, Sone T, Tanaka S, Soen S, Mori S, Hagino H, Fukunaga M, Nakamura T, Orimo H, Shiraki M, Adequate Treatment of Osteoporosis (A-TOP) research group.

2023-01-287 citations

10.1007/s00223-023-01060-9

Randomized head-to-head comparison of minodronic acid and raloxifene for fracture incidence in postmenopausal Japanese women: the Japanese Osteoporosis Intervention Trial (JOINT)-04.

Uemura Y, Sone T, Tanaka S, Miyazaki T, Tsukiyama M, Taguchi A, Soen S, Mori S, Hagino H, Sugimoto T, Fukunaga M, Ohta H, Nakamura T, Orimo H, Shiraki M, Adequate Treatment of Osteoporosis (A-TOP) Research Group.

2020-09-144 citations

10.1080/03007995.2020.1816537

Study design of multi-center, open-label randomized controlled, head-to-head trial comparing minodronic acid and raloxifene: Japanese Osteoporosis Intervention Trial (JOINT)-04.

Uemura Y, Tanaka S, Miyazaki T, Tsukiyama M, Sone T, Taguchi A, Soen S, Mori S, Hagino H, Sugimoto T, Fukunaga M, Ohta H, Nakamura T, Orimo H, Shiraki M, Adequate Treatment of Osteoporosis (A-TOP) research group.

2018-07-176 citations

10.1007/s00774-018-0942-z

Interventions

minodronic acid hydroate raloxifene hydorocloride

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Women over 60,one or more risk of A-TOP risk factors for fractur ken

Exclusion criteria

Exclusion criteria: Using therapeutic drug contraindications,Secondary osteoporousis and Disease with low bone mass, Advanced variant T4-L4, Heart disease,liver disease,kidney failure or other serious complications Problems with the reliability of interview data Treatment of malignant tumors that may affect bone metabolism

Design outcomes

Primary

Measure	Time frame
Osteoporotic fractures,Vertebral fractures,Major osteoporotic fractures	—

Secondary

Measure	Time frame
Bone density,HSA,height,Bone-related markers,lipid,Oral interview surveys,the number of falls,falls score,care level,morter function,QOL,Safty	—

Countries

Japan

Contacts

Public ContactYoji Mitadera

Public Health Research Foundation Comprehensive Support Project for Adequate Treatment of Osteoporosis

a-top@csp.or.jp03-5287-2638

Outcome results

None listed